- Home
- OZ vs KRRO Comparison
OZ vs KRRO Comparison
Compare OZ & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OZ
- KRRO
- Stock Information
- Founded
- OZ 2020
- KRRO 2014
- Country
- OZ United States
- KRRO United States
- Employees
- OZ N/A
- KRRO N/A
- Industry
- OZ
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- OZ
- KRRO Health Care
- Exchange
- OZ Nasdaq
- KRRO Nasdaq
- Market Cap
- OZ 236.3M
- KRRO 209.6M
- IPO Year
- OZ N/A
- KRRO 2019
- Fundamental
- Price
- OZ $63.75
- KRRO $15.56
- Analyst Decision
- OZ
- KRRO Strong Buy
- Analyst Count
- OZ 0
- KRRO 7
- Target Price
- OZ N/A
- KRRO $90.67
- AVG Volume (30 Days)
- OZ 6.0K
- KRRO 102.4K
- Earning Date
- OZ 01-01-0001
- KRRO 05-07-2025
- Dividend Yield
- OZ N/A
- KRRO N/A
- EPS Growth
- OZ N/A
- KRRO N/A
- EPS
- OZ N/A
- KRRO N/A
- Revenue
- OZ $2,675,000.00
- KRRO $4,821,000.00
- Revenue This Year
- OZ N/A
- KRRO N/A
- Revenue Next Year
- OZ N/A
- KRRO $55.56
- P/E Ratio
- OZ N/A
- KRRO N/A
- Revenue Growth
- OZ 18.68
- KRRO N/A
- 52 Week Low
- OZ $56.77
- KRRO $11.13
- 52 Week High
- OZ $82.89
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- OZ 53.29
- KRRO 45.62
- Support Level
- OZ $62.95
- KRRO $13.40
- Resistance Level
- OZ $64.50
- KRRO $22.15
- Average True Range (ATR)
- OZ 0.96
- KRRO 2.47
- MACD
- OZ 0.31
- KRRO 0.07
- Stochastic Oscillator
- OZ 78.43
- KRRO 24.69
About OZ Belpointe PREP LLC Units
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.